Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

COVID-19 and Cancer Consortium

doi:10.1186/s12885-023-10708-6

Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

COVID-19 and Cancer Consortium

Vagelos College of Physicians and Surgeons

Résultat de recherche › examen par les pairs

2 Citations (Scopus)

Résumé

Introduction: COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 severity among patients with melanoma, particularly assessing outcomes of patients on active targeted or immune therapy. Methods: Using the COVID-19 and Cancer Consortium (CCC19) registry, we identified 307 patients with melanoma diagnosed with COVID-19. We used multivariable models to assess demographic, cancer-related, and treatment-related factors associated with COVID-19 severity on a 6-level ordinal severity scale. We assessed whether treatment was associated with increased cardiac or pulmonary dysfunction among hospitalized patients and assessed mortality among patients with a history of melanoma compared with other cancer survivors. Results: Of 307 patients, 52 received immunotherapy (17%), and 32 targeted therapy (10%) in the previous 3 months. Using multivariable analyses, these treatments were not associated with COVID-19 severity (immunotherapy OR 0.51, 95% CI 0.19 – 1.39; targeted therapy OR 1.89, 95% CI 0.64 – 5.55). Among hospitalized patients, no signals of increased cardiac or pulmonary organ dysfunction, as measured by troponin, brain natriuretic peptide, and oxygenation were noted. Patients with a history of melanoma had similar 90-day mortality compared with other cancer survivors (OR 1.21, 95% CI 0.62 – 2.35). Conclusions: Melanoma therapies did not appear to be associated with increased severity of COVID-19 or worsening organ dysfunction. Patients with history of melanoma had similar 90-day survival following COVID-19 compared with other cancer survivors.

Langue d'origine	English
Numéro d'article	265
Journal	BMC Cancer
Volume	23
Numéro de publication	1
DOI	https://doi.org/10.1186/s12885-023-10708-6
Statut de publication	Published - déc. 2023

Financement

We thank all members of the CCC19 steering committee for their invaluable guidance of the CCC19 consortium. COVID-19 and Cancer Consortium (CCC-19) List of participants in CCC-19 by institution Sonya A. Reid1, MD, MPH; Alicia Beeghly1, MPH, PhD; Alaina J. Brown1, MD, MPH; Alex Cheng1, PhD; Sarah Croessmann1, PhD; Elizabeth J. Davis1, MD; Kyle T. Enriquez, MSc BS; Erin A. Gillaspie1, MD, MPH; Daniel Hausrath1, MD; Douglas B. Johnson1, MD, MSCI; Xuanyi Li1, MD; Sanjay Mishra1, MS, PhD; David A. Slosky1, MD; Carmen C. Solorzano1, MD, FACS; Matthew D. Tucker1, MD; Karen Vega-Luna1, MA; Lucy L. Wang1, BA, Trisha M. Wise-Draper3, MD, PhD; Syed A. Ahmad3, MD, FACS; Punita Grover3, MD; Shuchi Gulati3, MD; Jordan Kharofa3, MD; Tahir Latif3, MBBS, MBA; Michelle Marcum3, MS; Davendra P. S. Sohal3, MD, MPH; Olga Zamulko3, MD, Toni K. Choueiri, MD4; Ziad Bakouny4, MD, MSc; Jean M. Connors4, MD; George D. Demetri4, MD, FASCO; Narjust Duma4, MD; Dory A. Freeman4, BS; Antonio Giordano4, MD, PhD; Chris Labaki4, MD; Alicia K. Morgans4, MD, MPH; Anju Nohria4, MD; Renee-Maria Saliby4, MD, MSc; Andrew L. Schmidt4, MD; Eliezer M. Van Allen4, MD; Wenxin Xu4, MD; Rebecca L. Zon4, MD, Clara Hwang5, MD; Shirish M. Gadgeel5, MD; Sheela Tejwani5, MD, Christopher R. Friese6, PhD, RN, AOCN, FAAN; Leslie A. Fecher6, MD; Anne Boldt6, MD; James J. Yoon6, MD, Brandon Hayes-Lattin7, MD, FACP; Aaron M. Cohen7, MD, MS; Shannon McWeeney7, PhD; Eneida R. Nemecek7, MD, MS, MBA; Staci P. Williamson7, BS, Mehmet A. Bilen8, MD; Cecilia A. Castellano8; Deepak Ravindranathan8, MD, MS, Gary H. Lyman9, MD, MPH, FASCO, FRCP; Jerome J. Graber9, MD, MPH; Petros Grivas9, MD, PhD; Jessica E. Hawley9, MD; Elizabeth T. Loggers9, MD, PhD; Ryan C. Lynch9, MD; Elizabeth S. Nakasone9, MD, PhD; Michael T. Schweizer9, MD; Lisa Tachiki9, MD; Shaveta Vinayak9, MD, MS; Michael J. Wagner9, MD; Albert Yeh9, MD, Sumit A. Shah10, MD, MPH; Elwyn C. Cabebe10, MD; Michael J. Glover10, MD; Alokkumar Jha10, PhD; Ali Raza Khaki10, MD; Lidia Schapira10, MD, FASCO; Julie Tsu-Yu Wu10, MD, PhD, Daniel B. Flora11, MD, PharmD; Goetz Kloecker11, MD; Barbara B. Logan11, MS; Chaitanya Mandapakala11, MD, Elizabeth Wulff-Burchfield12, MD; Anup Kasi12, MD, MPH; Crosby D. Rock12, MD, Dimitrios Farmakiotis13, MD, FACP, FIDSA; Panos Arvanitis13, MS; Pamela C. Egan13, MD; Hina Khan13, MD; Elizabeth J. Klein13, BA; Adam J. Olszewski13, MD; Kendra Vieira13, BS; Jeremy L. Warner13, MD, MS, FAMIA, FASCO, Lisa B. Weissmann14, MD; Padmanabh S. Bhatt14, MD; Chinmay Jani14, MD; Melissa G. Mariano14, DO; Carey C. Thomson14, MD, FCCP, MPH, Matthew Puc15, MD; Theresa M. Carducci15, MSN, RN, CCRP; Karen J. Goldsmith15, BSN, RN; Susan Van Loon15, RN, CTR, CCRP, Daniel Y. Reuben16, MD, MS; Mariam Alexander16, MD, PhD; Sara Matar16, MD; Sarah Mushtaq16, MD, Keith E. Stockerl-Goldstein17, MD; Omar Butt17, MD, PhD; Mark A. Fiala17, MSW; Jeffrey P. Henderson17, MD, PhD; Ryan S. Monahan17, MBA; Alice Y. Zhou17, MD, PhD, Philip E. Lammers18, MD, MSCI, Sanjay G. Revankar19, MD, FIDSA, Salvatore A. Del Prete20, MD; Michael H. Bar20, MD, FACP; Anthony P. Gulati20, MD; K. M. Steve Lo20, MD; Suzanne J. Rose20, MS, PhD, CCRC, FACRP; Jamie Stratton20, MD; Paul L. Weinstein20, MD, Shilpa Gupta21, MD; Nathan A. Pennell21, MD, PhD, FASCO; Manmeet S. Ahluwalia21, MD, FACP; Scott J. Dawsey21, MD; Christopher A. Lemmon21, MD; Amanda Nizam21, MD; Nima Sharifi21, MD, Claire Hoppenot22, MD; Ang Li, MD, MS , Susan Halabi23, PhD, FASCO, FSCT, FASA; Hannah Dzimitrowicz23, MD; Tian Zhang23, MD, MHS, Sharad Goyal24, MD; Minh-Phuong Huynh-Le24, MD, MAS, Peter Paul Yu25, MD, FACP, FASCO; Jessica M. Clement25, MD; Ahmad Daher25, MD; Mark E. Dailey25, MD; Rawad Elias25, MD; Asha Jayaraj25, MD; Emily Hsu25, MD; Alvaro G. Menendez25, MD; Oscar K. Serrano25, MD, MBA, FACS, Melissa K. Accordino26, MD, MS; Divaya Bhutani26, MD; Dawn Hershman26, MD, MS, FASCO; Matthew A. Ingham26, MD; Gary K. Schwartz26, MD, Eric H. Bernicker27, MD, John F. Deeken28, MD; Danielle Shafer28, DO, Erika Ruíz-García29, MD, MCs; Ana Ramirez29, MD; Diana Vilar-Compte29, MD, MsC, Mark A. Lewis30, MD; Terence D. Rhodes30, MD, PhD; David M. Gill30, MD; Clarke A. Low30, MD, Sandeep H. Mashru31, MD; Abdul-Hai Mansoor31, MD, Grant C. Lewis32, MD; Stephanie J. Smith32, RN, MSN, OCN; Howard A. Zaren32, MD, FACS, Gayathri Nagaraj33, MD; Mojtaba Akhtari33, MD; Dan R. Castillo33, MD; Eric Lau33, DO; Mark E. Reeves33, MD, PhD, Stephanie Berg34, DO; Natalie Knox34, BS; Timothy E. O'Connor34, MD, Eric B. Durbin35, DrPH, MS, Amit A. Kulkarni36, MD; Heather H. Nelson36, PhD, MPH; Zohar Sachs36, MD, PhD, Rachel P. Rosovsky37, MD, MPH; Kerry L. Reynolds37, MD; Aditya Bardia37, MD; Genevieve Boland37, MD, PhD, FACS; Justin F. Gainor37, MD; Leyre Zubiri37, MD, PhD, Thorvardur R. Halfdanarson38, MD; Tanios S. Bekaii-Saab38, MD, FACP; Aakash Desai38, MD, MPH; Irbaz B. Riaz38, MD, MS; Surbhi Shah38, MD; Katherine E. Smith38, MD; Colt Williams38, MD, Nathaniel Bouganim39, MD, FRCP(C); Arielle Elkrief39, MD, FRCP(C); Justin Panasci39; Donald C. Vinh39, MD, FRCP(C), Gregory J. Riely40, MD, PhD; Rimma Belenkaya40, MA, MS; John Philip40, MS, Bryan Faller41, MD, Rana R. McKay42, MD; Archana Ajmera42, MSN, ANP-BC, AOCNP; Sharon S. Brouha42, MD, MPH; Sharon Choi42, MD, PhD; Albert Hsiao42, MD, PhD; Seth Kligerman42, MD; Taylor K. Nonato42; Erin G. Reid42, MD, Sibel Blau43, MD, Sachin R. Jhawar44, MD; Daniel Addison44, MD; James L. Chen44, MD; Margaret E. Gatti-Mays44, MD; Vidhya Karivedu44, MBBS; Joshua D. Palmer44, MD; Daniel G. Stover44, MD; Sarah Wall44, MD; Nicole O. Williams44, MD, Monika Joshi45, MD, MRCP; Hyma V. Polimera45, MD; Lauren D. Pomerantz45; Marc A. Rovito45, MD, FACP, Elizabeth A. Griffiths46, MD; Pragati G. Advani46, MD, MPH; Igor Puzanov46, MD, MSCI, FACP, Salma K. Jabbour47, MD; Christian F. Misdary47, MD; Mansi R. Shah47, MD, Gerald Batist48, MD, FACP, FRCP; Erin Cook48, MSN; Miriam Santos Dutra48, PhD; Cristiano Ferrario48, MD; Wilson H. Miller Jr.48, MD, PhD, Babar Bashir49, MD, MS; Christopher McNair49, PhD; Sana Z. Mahmood49, BA, BS; Vasil Mico49, BS; Andrea Verghese Rivera49, MD, Natasha C. Edwin50MD; Melissa Smits50, APC, Deborah B. Doroshow51, MD, PhD; Matthew D. Galsky51, MD; Michael Wotman51, MD, Alyson Fazio52, APRN-BC; Julie C. Fu52, MD; Kathryn E. Huber52, MD; Mark H. Sueyoshi52, MD, Vadim S. Koshkin53, MD; Hala T. Borno53, MD; Daniel H. Kwon53, MD; Eric J. Small53, MD; Sylvia Zhang53, MS, Samuel M. Rubinstein54, MD; William A. Wood54, MD, MPH; Tessa M. Andermann54, MD; Christopher Jensen54, MD, Daniel W. Bowles55, MD; Christoper L. Geiger55, MD, Lawrence E. Feldman56, MD; Kent F. Hoskins56, MD; Gerald Gantt Jr.56, MD; Li C. Liu56, PhD; Mahir Khan56, MD; Ryan H. Nguyen56, DO; Mary Pasquinelli56, APN, DNP; Candice Schwartz56, MD; Neeta K. Venepalli56, MD, MBA, Blanche H. Mavromatis57, MD; Ragneel R. Bijjula57, MD; Qamar U. Zaman57, MD, David M. Aboulafia58, MD; Brett A. Schroeder58, MD, Umit Topaloglu59, PhD, FAMIA; Saif I. Alimohamed59, MD, Joan K. Moore60, MSN, RN, OCN, CCRP, Prakash Peddi61, MD; Lane R. Rosen61, MD; Briana Barrow McCollough61, BSc, CCRC, Navid Hafez62, MD, MPH; Roy Herbst62, MD, PhD; Patricia LoRusso62, DO, PhD; Maryam B. Lustberg62, MD, MPH; Tyler Masters62, MS; Catherine Stratton62, BA. Affiliations:1Vanderbilt University Medical Center, Nashville, TN, USA;2Georgetown Lombardi Comprehensive Cancer Center at Georgetown University, Washington DC, USA;3University of Cincinnati Cancer Center, Cincinnati, OH, USA;4Dana-Farber Cancer Institute, Boston, MA, USA;5Henry Ford Cancer Institute, Henry Ford Hospital, Detroit, MI, USA6University of Michigan Rogel Cancer Center, Ann Arbor MI, USA7Knight Cancer Institute at Oregon Health and Science University, Portland, OR, USA,8Winship Cancer Institute of Emory University, Atlanta GA, USA,9Fred Hutchinson Cancer Center, Seattle WA, USA,10Stanford Cancer Institute at Stanford University, Palo Alto CA, USA11St. Elizabeth Healthcare, Edgewood, KY, USA,12The University of Kansas Cancer Center, Kansas City, Kansas, USA,13Brown University and Lifespan Cancer Institute, Providence RI, USA,14Mount Auburn Hospital, Cambridge, MA, USA,15Virtua Health, Marleton, NJ, USA,16Hollings Cancer Center at the Medical University of South Carolina; Charleston, SC, USA,17Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital, St. Louis, MO, USA;18Baptist Cancer Center, Memphis, TN, USA;19The Barbara Ann Karmanos Cancer Institute at Wayne State University School of Medicine, Detroit, MI, USA;20Carl & Dorothy Bennett Cancer Center at Stamford Hospital, Stamford, CT, USA;21Cleveland Clinic, Cleveland, OH, USA;22Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX, USA;23Duke Cancer Institute at Duke University Medical Center, Durham, NC, USA;24George Washington University, Washington, DC, USA;25Hartford HealthCare Cancer Institute, Hartford, CT, USA;26Herbert Irving Comprehensive Cancer Center at Columbia University, New York, NY, USA;27Houston Methodist Cancer Center, Houston, TX, USA;28Inova Schar Cancer Institute, Fairfax, VA, USA;29Instituto Nacional de Cancerologia, Mexico City, Mexico;30Intermountain Health Care, Salt Lake City, UT, USA;31Kaiser Permanente Northwest, OR/WA, USA;32Lewis Cancer and Research Pavilion @ St. Joseph’s/Candler, Savannah, GA, USA;33Loma Linda University Cancer Center, Loma Linda, CA, USA;34Loyola University Medical Center, Maywood, IL, USA;35Markey Cancer Center at the University of Kentucky, Lexington, KY, USA;36Masonic Cancer Center at the University of Minnesota, Minneapolis, MN, USA;37Massachusetts General Hospital Cancer Center, Boston, MA, USA;38Mayo Clinic, AZ/FL/MN, USA;39McGill University Health Centre, Montreal, QC, Canada;40Memorial Sloan Kettering Cancer Center, New York, NY, USA;41Missouri Baptist Medical Center, St. Louis, MO, USA;42Moores Comprehensive Cancer Center at the University of California, San Diego, La Jolla, CA, USA;43Northwest Medical Specialties, Tacoma, WA, USA;44The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA;45Penn State Health/Penn State Cancer Institute/St. Joseph Cancer Center, PA, USA;46Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA;47Rutgers Cancer Institute of New Jersey at Rutgers Biomedical and Health Sciences, New Brunswick, NJ, USA;48Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada;49Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA, USA;50ThedaCare Cancer Care, Appleton, WI, USA;51Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, New York, NY, USA;52Tufts Medical Center Cancer Center, Boston and Stoneham, MA, USA;53UCSF Helen Diller Family Comprehensive Cancer Center at the University of California at San Francisco, CA, USA;54UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA;55University of Colorado Cancer Center, Aurora, CO, USA;56University of Illinois Hospital & Health Sciences System, Chicago, IL, USA;57UPMC Western Maryland, Cumberland, MD, USA;58Virginia Mason Cancer Institute, Seattle, WA, USA;59Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA;60WellSpan Health, York, PA, USA;61Willis-Knighton Cancer Center, Shreveport, LA, USA;62Yale Cancer Center at Yale University School of Medicine, New Haven, CT, USA. REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS / NIH). This study was partly supported by grants from the National Cancer Institute [grant number P30 CA068485 to Vanderbilt University Medical Center]. The study was partly supported by grants from the Melanoma Research Foundation (to DBJ). CRF is supported by P30 CA046592 and T32 CA236621. CCF is supported by T32 CA217834-05. LT received grant funding from the NIH 5T32CA009515-37.

Bailleurs de fonds	Numéro du bailleur de fonds
25Hartford HealthCare Cancer Institute
27Houston Methodist Cancer Center
28Inova Schar Cancer Institute
33Loma Linda University Cancer Center
34Loyola University Medical Center
38Mayo Clinic
45Penn State Health/Penn State Cancer Institute/St
48Segal Cancer Centre, Jewish General Hospital
49Sidney Kimmel Cancer Center
4Dana-Farber Cancer Institute
51Tisch Cancer Institute
54UNC Lineberger Comprehensive Cancer Center
58Virginia Mason Cancer Institute
59Wake Forest Baptist Comprehensive Cancer Center
61Willis-Knighton Cancer Center, Shreveport
ANP-BC
APRN-BC
AZ/FL/MN
Cancer Consortium	CCC-19
FASA
FASCO
FSCT
Ford Cancer Institute
Henry Ford Hospital, Detroit, MI, USA6University of Michigan Rogel Cancer Center
MBBS
MSCI
Ohio State University Comprehensive Cancer Center
Wayne State University School of Medicine, Detroit, MI
Winston-Salem
National Institutes of Health
National Cancer Institute	P30 CA068485
Melanoma Research Foundation	P30 CA046592, T32 CA236621, T32 CA217834-05, 5T32CA009515-37
National Center for Advancing Translational Sciences
Vanderbilt Institute for Clinical and Translational Research	UL1 TR000445
University of Minnesota
Icahn School of Medicine at Mount Sinai
Baylor College of Medicine
UNIVERSITY OF CALIFORNIA, SAN DIEGO
Georgetown University
Thomas Jefferson University
McGill University
Malaysian Society Nephrology
Winship Cancer Institute
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
Association of Pathology Chairs
Barbara Ann Karmanos Cancer Institute
Cancer Center, University of Kansas
Clean Combustion Research Center, King Abdullah University of Science and Technology

ASJC Scopus Subject Areas

Oncology
Genetics
Cancer Research

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.1186/s12885-023-10708-6

Autres fichiers et liens

Citer

@article{b2112c7dfa8b4e45b86b319b9b147b85,

title = "Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma",

abstract = "Introduction: COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 severity among patients with melanoma, particularly assessing outcomes of patients on active targeted or immune therapy. Methods: Using the COVID-19 and Cancer Consortium (CCC19) registry, we identified 307 patients with melanoma diagnosed with COVID-19. We used multivariable models to assess demographic, cancer-related, and treatment-related factors associated with COVID-19 severity on a 6-level ordinal severity scale. We assessed whether treatment was associated with increased cardiac or pulmonary dysfunction among hospitalized patients and assessed mortality among patients with a history of melanoma compared with other cancer survivors. Results: Of 307 patients, 52 received immunotherapy (17%), and 32 targeted therapy (10%) in the previous 3 months. Using multivariable analyses, these treatments were not associated with COVID-19 severity (immunotherapy OR 0.51, 95% CI 0.19 – 1.39; targeted therapy OR 1.89, 95% CI 0.64 – 5.55). Among hospitalized patients, no signals of increased cardiac or pulmonary organ dysfunction, as measured by troponin, brain natriuretic peptide, and oxygenation were noted. Patients with a history of melanoma had similar 90-day mortality compared with other cancer survivors (OR 1.21, 95% CI 0.62 – 2.35). Conclusions: Melanoma therapies did not appear to be associated with increased severity of COVID-19 or worsening organ dysfunction. Patients with history of melanoma had similar 90-day survival following COVID-19 compared with other cancer survivors.",

author = "{COVID-19 and Cancer Consortium} and Johnson, {Douglas B.} and Atkins, {Michael B.} and Cassandra Hennessy and Trisha Wise-Draper and Hannah Heilman and Joy Awosika and Ziad Bakouny and Chris Labaki and Saliby, {Renee Maria} and Clara Hwang and Singh, {Sunny R.K.} and Nino Balanchivadze and Friese, {Christopher R.} and Fecher, {Leslie A.} and Yoon, {James J.} and Brandon Hayes-Lattin and Bilen, {Mehmet A.} and Castellano, {Cecilia A.} and Lyman, {Gary H.} and Lisa Tachiki and Shah, {Sumit A.} and Glover, {Michael J.} and Flora, {Daniel B.} and Elizabeth Wulff-Burchfield and Anup Kasi and Abbasi, {Saqib H.} and Dimitrios Farmakiotis and Kendra Viera and Klein, {Elizabeth J.} and Weissman, {Lisa B.} and Chinmay Jani and Matthew Puc and Fahey, {Catherine C.} and Reuben, {Daniel Y.} and Sanjay Mishra and Alicia Beeghly-Fadiel and Benjamin French and Warner, {Jeremy L.} and Reid, {Sonya A.} and Brown, {Alaina J.} and Alex Cheng and Sarah Croessmann and Davis, {Elizabeth J.} and Enriquez, {Kyle T.} and Gillaspie, {Erin A.} and Daniel Hausrath and Xuanyi Li and Slosky, {David A.} and Solorzano, {Carmen C.} and Dawn Hershman",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = dec,

doi = "10.1186/s12885-023-10708-6",

language = "English",

volume = "23",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

AU - COVID-19 and Cancer Consortium

AU - Johnson, Douglas B.

AU - Atkins, Michael B.

AU - Hennessy, Cassandra

AU - Wise-Draper, Trisha

AU - Heilman, Hannah

AU - Awosika, Joy

AU - Bakouny, Ziad

AU - Labaki, Chris

AU - Saliby, Renee Maria

AU - Hwang, Clara

AU - Singh, Sunny R.K.

AU - Balanchivadze, Nino

AU - Friese, Christopher R.

AU - Fecher, Leslie A.

AU - Yoon, James J.

AU - Hayes-Lattin, Brandon

AU - Bilen, Mehmet A.

AU - Castellano, Cecilia A.

AU - Lyman, Gary H.

AU - Tachiki, Lisa

AU - Shah, Sumit A.

AU - Glover, Michael J.

AU - Flora, Daniel B.

AU - Wulff-Burchfield, Elizabeth

AU - Kasi, Anup

AU - Abbasi, Saqib H.

AU - Farmakiotis, Dimitrios

AU - Viera, Kendra

AU - Klein, Elizabeth J.

AU - Weissman, Lisa B.

AU - Jani, Chinmay

AU - Puc, Matthew

AU - Fahey, Catherine C.

AU - Reuben, Daniel Y.

AU - Mishra, Sanjay

AU - Beeghly-Fadiel, Alicia

AU - French, Benjamin

AU - Warner, Jeremy L.

AU - Reid, Sonya A.

AU - Brown, Alaina J.

AU - Cheng, Alex

AU - Croessmann, Sarah

AU - Davis, Elizabeth J.

AU - Enriquez, Kyle T.

AU - Gillaspie, Erin A.

AU - Hausrath, Daniel

AU - Li, Xuanyi

AU - Slosky, David A.

AU - Solorzano, Carmen C.

AU - Hershman, Dawn

PY - 2023/12

Y1 - 2023/12

N2 - Introduction: COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 severity among patients with melanoma, particularly assessing outcomes of patients on active targeted or immune therapy. Methods: Using the COVID-19 and Cancer Consortium (CCC19) registry, we identified 307 patients with melanoma diagnosed with COVID-19. We used multivariable models to assess demographic, cancer-related, and treatment-related factors associated with COVID-19 severity on a 6-level ordinal severity scale. We assessed whether treatment was associated with increased cardiac or pulmonary dysfunction among hospitalized patients and assessed mortality among patients with a history of melanoma compared with other cancer survivors. Results: Of 307 patients, 52 received immunotherapy (17%), and 32 targeted therapy (10%) in the previous 3 months. Using multivariable analyses, these treatments were not associated with COVID-19 severity (immunotherapy OR 0.51, 95% CI 0.19 – 1.39; targeted therapy OR 1.89, 95% CI 0.64 – 5.55). Among hospitalized patients, no signals of increased cardiac or pulmonary organ dysfunction, as measured by troponin, brain natriuretic peptide, and oxygenation were noted. Patients with a history of melanoma had similar 90-day mortality compared with other cancer survivors (OR 1.21, 95% CI 0.62 – 2.35). Conclusions: Melanoma therapies did not appear to be associated with increased severity of COVID-19 or worsening organ dysfunction. Patients with history of melanoma had similar 90-day survival following COVID-19 compared with other cancer survivors.

AB - Introduction: COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 severity among patients with melanoma, particularly assessing outcomes of patients on active targeted or immune therapy. Methods: Using the COVID-19 and Cancer Consortium (CCC19) registry, we identified 307 patients with melanoma diagnosed with COVID-19. We used multivariable models to assess demographic, cancer-related, and treatment-related factors associated with COVID-19 severity on a 6-level ordinal severity scale. We assessed whether treatment was associated with increased cardiac or pulmonary dysfunction among hospitalized patients and assessed mortality among patients with a history of melanoma compared with other cancer survivors. Results: Of 307 patients, 52 received immunotherapy (17%), and 32 targeted therapy (10%) in the previous 3 months. Using multivariable analyses, these treatments were not associated with COVID-19 severity (immunotherapy OR 0.51, 95% CI 0.19 – 1.39; targeted therapy OR 1.89, 95% CI 0.64 – 5.55). Among hospitalized patients, no signals of increased cardiac or pulmonary organ dysfunction, as measured by troponin, brain natriuretic peptide, and oxygenation were noted. Patients with a history of melanoma had similar 90-day mortality compared with other cancer survivors (OR 1.21, 95% CI 0.62 – 2.35). Conclusions: Melanoma therapies did not appear to be associated with increased severity of COVID-19 or worsening organ dysfunction. Patients with history of melanoma had similar 90-day survival following COVID-19 compared with other cancer survivors.

UR - http://www.scopus.com/inward/record.url?scp=85150805325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150805325&partnerID=8YFLogxK

U2 - 10.1186/s12885-023-10708-6

DO - 10.1186/s12885-023-10708-6

M3 - Article

C2 - 36949413

AN - SCOPUS:85150805325

SN - 1471-2407

VL - 23

JO - BMC Cancer

JF - BMC Cancer

IS - 1

M1 - 265

ER -

Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

Résumé

Financement

ASJC Scopus Subject Areas

ODD de l’ONU

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer